Seasonal and Geographical Trends in Photodynamic Therapy and Cryosurgery Utilization in the United States: A Cross=Sectional Study from 2015-2022

Dawn Merritt; Jon Lyons; Mouna Mikati; Todd Schlesinger

doi:10.25251/skin.7.supp.288

Dr. Dawn Merritt

OhioHealth, Columbus, OH, USA

Dr. Jon Lyons

Biofrontera Inc. Medical Affairs, Woburn, MA, USA

Dr. Mouna Mikati

a:1:{s:5:"en_US";s:11:"Biofrontera";}

Dr. Todd Schlesinger

Clinical Research Center of the Carolinas, South Carolina, USA

Keywords

Photodynamic therapy, cryosurgery, HCPCS, actinic keratosis, seasonality trends, geographical trends, CPT codes

References

1. Martinez-Carpio, PA et al. Laser Ther. 2012;2(3):199-208

2. Andrews MD. Am Fam Physician. 2004;69(10):2365-2372

3. Farberg AS, et al. Dermatol Ther (Heidelb). 20123;13(3):689-716

4. National Oceanic and Atmospheric Administration. Meteorological versus astronomical seasons. Available from https://www.ncel.noaa.gov/news/meteorological-versus-astronomical-seasons. Access Sept 8, 2023.

PDF

Published

Nov 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.288

How to Cite

Merritt, D., Lyons, J., Mikati, M., & Schlesinger, T. (2023). Seasonal and Geographical Trends in Photodynamic Therapy and Cryosurgery Utilization in the United States: A Cross=Sectional Study from 2015-2022. SKIN The Journal of Cutaneous Medicine, 7(6), s288. https://doi.org/10.25251/skin.7.supp.288

Issue

Vol. 7 No. 6 (2023): November 2023 Issue

Section

Miscellaneous

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan, Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Danny Zakria, April Armstrong, Brian Berman, James Del Rosso, Mark Lebwohl, Todd Schlesinger, Darrell Rigel, The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee, Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl, Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Brian Berman, Todd Schlesinger, Neal Bhatia, Ayman Grada, Laura Padulles, Francisco Hernandez, david Cutler, Mark Lebwohl, Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Laura Padulles, Francisco Hernandez, David Cutler, Mark Lebwohl, Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Leon Kircik, Todd Schlesinger, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Todd Schlesinger, Leon Kircik, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Mark Lebwohl, Vishal A. Patel, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
April W. Armstrong, Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, Bruce Strober, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

1 2 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)